BioLineRx Ltd. (BLRX) Form 6-K — Aug 18, 2026
BioLineRx (Nasdaq and TASE: BLRX) has called its Annual General Meeting of Shareholders for September 23, 2026, with a record date of August 24, 2026 and a quorum of 25% of voting rights. Shareholders will vote on five proposals, all recommended by the board. The most consequential proposal is a five-fold increase in authorized share capital, from 20 billion to 100 billion ordinary shares (NIS 2.0 billion to NIS 10.0 billion nominal), citing future strategic transactions, offerings to fund operations, and additional equity grants. No specific issuance is planned now.
Key figures
- Shares Outstanding
- 2620977190
- Ads ratio
- 1 ADS = 600 ordinary shares
- Ceo psu ads
- 73500
- Record date
- 2026-08-24
- Meeting date
- 2026-09-23
- Ceo option ads
- 94900
- Ceo psu shares
- 44100000
- Ceo option shares
- 56940000
- Quorum requirement
- 25% of voting rights
- Director option ads each
- 10000
- Authorized shares current
- 20000000000
- Authorized shares proposed
- 100000000000
- Unissued unreserved shares
- 15815283331
- Director option shares each
- 6000000
- Shares reserved equity plan
- 313240800
- Auditor fees 2024 usd thousands
- 241
- Auditor fees 2025 usd thousands
- 188
- Insider director ownership shares
- 54589800
- Option exercise price per ads usd
- 3.33
- Authorized share increase multiple
- 5x
- Insider director ownership percent
- 2.01%
- Shares reserved outstanding warrants
- 1250498679
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.